Image Place holder

Iman Imanirad, MD


Specialty: Medical Oncology
Program: Gastrointestinal Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Education & Training

Board Certification:

  • Hematology
  • Internal Medicine
  • Medical Oncology
  • Internal Medicine

Fellowship:

  • University of Florida College of Medicine - Hematology Oncology

Residency:

  • University of Florida College of Medicine - Internal Medicine

Medical School:

  • Saba University of Medical Sciences - MD
Participating Trials

CLINICAL TRIAL 19680
Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-Type MSS Refractory Metastatic Colorectal Adenocarcinoma
Condition: Gastrointestinal Tumor
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Panitumumab; Vectibix (Panitumumab); Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19112
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19594
A Multicenter, Non-Randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination with Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma (HCC) with No Prior Systemic Therapy.
Condition: Gastrointestinal Tumor
Intervention:
Open

CLINICAL TRIAL 19693
A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil; BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab); cisplatin
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-033; TSR-042
Open

CLINICAL TRIAL 19682
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation
Condition: Gastrointestinal Tumor
Intervention: BMS-936558 (Nivolumab); Nivolumab; Placebo
Open

CLINICAL TRIAL 19581
Phase I study of Regorafenib and Nivolumab in Mismatch Repair (MMR) Proficient Advanced Refractory Colorectal Cancer
Condition: Gastrointestinal Tumor
Intervention: BAY 73-4506 (Regorafenib); BMS-936558 (Nivolumab); Nivolumab; Regorafenib (Stivarga)
Open

CLINICAL TRIAL 19732
Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (Cabinet)
Condition: Gastrointestinal Tumor
Intervention: Cabozantinib (XL 184); Placebo
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Cogle CR, Iannacone MR, Yu D, Cole AL, Imanirad I, Yan L, Mackinnon JA, List AF, Rollison DE. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. Leuk Res. 2014 Jan;38(1):71-75. Pubmedid: 24280283.
  • Dallas J, Imanirad I, Rajani R, Dagan R, Subbiah S, Gaa R, Dwarica WA, Ivey AM, Zlotecki RA, Malyapa R, Indelicato DJ, Scarborough MT, Reith JD, Gibbs CP, Dang LH. Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: a case report. J Med Case Rep. 2012 Jan;6:41. Pubmedid: 22289277. Pmcid: PMC3277477.
  • Imanirad I, Rajasekhar A, Zumberg M. A case series of atypical presentations of thrombotic thrombocytopenic purpura. J Clin Apher. 2012 Aug;27(4):221-226. Pubmedid: 22467376.
  • Santos N, Wenger JB, Havre P, Liu Y, Dagan R, Imanirad I, Ivey AM, Zlotecki RA, Algood CB, Gilbert SM, Allegra CJ, Okunieff P, Vieweg J, Dang NH, Luesch H, Dang LH. Combination therapy for renal cell cancer: what are possible options?. Oncology-Basel. 2012 Apr;81(3-4):220-229. Pubmedid: 22085914. Pmcid: PMC3225259.
  • Cogle CR, Imanirad I, Wiggins LE, Hsu J, Brown R, Scornik JC, Wingard JR. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol. 2010 Jan;8(1):40-46. Pubmedid: 20351682.